Cancer Cell Research


Contact Us


Chronic Diseases Prevention Review








Cancer Cell Research











Chronic  Diseases Prevention Review








Cancer Cell Research

Article: Prognostic value of combination fibrinogen, platelet, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced lung adenocarcinoma

by Leirong Wang, Xiaorui Chi, Lingxin Feng, Zhuang Yu

Cancer Cell Research 2019 6(23) 650-658; published online  28  September 2019

Abstract: A combination of fibrinogen (FBG), platelet (PLT), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) (abbreviated as CO-NPF) has been recently evaluated as a marker for prognostication in lung cancer. While previous study on CO-NPF has evaluated in lung adenosquamous patients, the combination of these four markers has not been evaluated in advanced lung adenocarcinoma yet. In this study, we investigated the significance of CO-NPF in predicting the survival of patients with advanced lung adenocarcinoma. 225 patients with pathologically diagnosed lung adenocarcinoma were enrolled. The cutoff values for FBG, PLT, NLR and PLR were defined by receiver operating characteristic (ROC). The CO-NPF was calculated as the combination of FBG, PLT, NLR and PLR based on these cutoff values. Kaplan-Meier analysis and Cox proportional hazard models were used to assess the prognostic value of CO-NPF. Kaplan-Meier analysis reveals that CO-NFP was associated with poorer progressive free survival (PFS) [hazard ratio (HR), 0.657; 95% confidence interval (CI), 0.501-0.862; P=0.002] and overall survival (OS) (HR, 0.701; 95% CI, 0.523-0.938; P=0.016). Cox proportional hazard models further reveals CO-NFP as an independent prognostic factor for PFS (HR, 0.665; 95% CI, 0.504-0.876; P=0.004) and OS (HR, 0.672; 95% CI, 0.495-0.914; P=0.011). CO-NPF can serve as a useful biomarker to predict recurrence and death for patients with advanced lung adenocarcinoma.

Open Access Download (free) PDF

Article: The potential use and clinical significance of plasma RIPK3 in distinguishing malignant from benign lung lesions

by Wei Sun, Wencheng Yu, Yanan Zhang, Shichao Cui

Cancer Cell Research 2019 6(23) 659-665; published online 28 September 2019

Abstract: To evaluate the potential value of the plasma level of receptor- interacting protein kinase 3 (RIPK3), a key protein involved in the activation of necroptosis, as a biomarker for the differential diagnosis of lung cancer in patients with lung lesions detected by chest computed tomography. The subjects of this study were divided into 3 groups: lung cancer (n = 30), benign disease (n = 13), and healthy controls (n = 33). The measurement of plasma RIPK3 was performed by enzyme-linked immunosorbent assay. The plasma RIPK3 level in patients with lung cancer (1467.4 ± 347.4 pg/ml) was significantly higher than that in patients with benign disease (1219.8 ± 156.4 pg/ml) and healthy controls (746.2 ± 255.3 pg/ml). Besides, plasma RIPK3 levels that were greater than 970.06 pg/ml provided 96.7% sensitivity and 84.8% specificity for lung cancer. Our results show that plasma RIPK3 levels are higher in lung cancer patients. We suggest that plasma RIPK3 level could be used as an auxiliary tool for distinguishing lung cancer from benign lesions and healthy lungs.

Open Access Download (free) PDF

Chronic Diseases Prevention Review

Article: Vivo study of MSCs on EPCs cells in ischemic heart disease

by Jianming Wang, Gengbiao Chen, Youfeng Guo, Xiaohong Yin, Xiaodong Wang

Chronic Diseases Prevention Review 2019 3(12) 1-5; published online 18 July 2019

Abstract: The treatment of ischemic heart disease mainly depends on the formation of blood vessels and the survival of cardiac myocytes. This paper will research the enhancement of EPC cells by mesenchymal stem cells in the treatment of ischemic heart disease. Mouse bone marrow was collected, MSCs cells were isolated and cultured. Flow cytometry was used to test the expression of CD34 and CD44. Then MSCs cells and endothelial progenitor cells co-culture 48 h, and 24 Wistar rats were randomly divided into EPCs group, EPCs MSCs + group and the control group. MSCs 2×106, EPCs 2×106, EPCs 2×106, and PBS buffer were injected into five different regions around ischemic myocardium. The changes in cardiac function were assessed by echocardiography after 4 weeks. MSCs 2×106, EPCs 2×106, EPCs 2×106, and PBS buffer were injected into five different regions around ischemic myocardium. The changes in cardiac function were assessed by echocardiography after 4 weeks. The rats were sacrificed, and the expression of VEGF was detected by immunohistochemistry and immunofluorescence. The surface markers CD34 and CD44 of MSCs and EPCs were differentially expressed. We successfully isolated MSCs and EPCs cells. Meanwhile, the proliferation index Ki67 was highly expressed, suggesting that MSCs could effectively promote the proliferation activity of EPCs. Echocardiography showed that after MSCs+EPCs treatment, the left ventricular ejection fraction, end-diastolic volume and cardiac volume of the rats were significantly improved, with statistically significant differences from the control group and the EPCs group (P<0.05), Meanwhile, the expression of VEGF in MSCs+EPCs group was also significantly increased (P<0.05). Mesenchymal stem cells can enhance the therapeutic effect of EPC cells in ischemic heart disease, which can promote myocardial angiogenesis, improve ventricular remodeling and cardiac function.

Open Access Download (free) PDF

Article:  Early Screening and Diagnosis of Autism

by Zhongjie An

Chronic Diseases Prevention Review 2019 3(12) 39-44; published online 28 December 2019

Abstract:  Autism Spectrum Disorders have for some time been the focus of intense interest for clinicians and researchers because of the high prevalence of the disorders among children in the community. Particular attention has been paid to the early diagnosis of the disorder and to the intensive therapeutic intervention. Currently the best prognosis for autism lays in the early diagnosis and intervention. But diagnosis of autism at an early age is challenging due to the existing phenotypic and etiological heterogeneity among ASD individuals. There are many screening scales for autism, but their specificity and sensitivity vary to varying degrees. Therefore, an efficient early diagnosis method is needed. This paper presents a review of the early detection of ASD.

Open Access Download (free) PDF